TFF Pharmaceuticals — Investor Presentation (March 2022)
34 slides from TFF Pharmaceuticals's investor presentation, Mar 24, 2022
Slide 1: Better Delivery, Better Therapy: Powerful Drug Delivery Solutions
1 Better Delivery, Better Therapy: Powerful Drug Delivery Solutions Corporate Investor Presentation March 2022 Nasdaq: TFFP
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This document contains forward - looking statements concerning TFF Pharmaceuticals, Inc. (“TFF”, the “Company,” “we,” “us,” and “our”). The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,”
Slide 3: Investment Highlights
3 Investment Highlights Experienced Management; IP Protection Four Internal Programs Broadly Applicable Platform Proprietary Pulmonary Drug Delivery Process • Experienced senior management team with outstanding track record of success in a diverse set of competencies and related disciplines. • Robus
Slide 4: TFF Leadership
4 TFF Leadership • 30 years of business leadership experience in development and commercial launches of global therapeutics • Former CEO of Tibotec Therapeutics, a J&J company, and Rhone - Poulenc Rorer/Canada, and in addition to other senior C - suite positions at Centocor and J&J • Critical roles
Slide 5: Scientific Advisory Board
5 Scientific Advisory Board David N. Cornfield, M.D. Professor of Pulmonary Medicine, Stanford University Ted M. Ross, Ph.D. Professor, Center for Vaccines and Immunology, Department of Infectious Diseases, University of Georgia Prof. David Denning, FRCP, FRCPath, DCH, FMedSci Professor of Infectiou
Slide 6: TFF Pipeline – Building value through internal programs
6 TFF Pipeline – Building value through internal programs Category Platform Formulation Indication Development Stage (& Partners) Recent and Anticipated Milestones Pre - clinical Phase 1 Phase 2 Phase 3 Internal TFF VORI 1 Inhaled Voriconazole (Antifungal) Invasive Pulmonary Aspergillosis (IPA) • Fi
Slide 7: TFF External Pipeline – Leveraging the TFF platform
7 TFF External Pipeline – Leveraging the TFF platform Category Platform Formulation Indication Development Stage (& Partners) Recent and Anticipated Milestones Pre - clinical Phase 1 Partner External Vaccines Inhaled and intranasal delivery Influenza, Ebola, Marburg, COVID - 19 and alphaviruses • In
Slide 8: Thin Film Freezing – Superior Pulmonary Drug Delivery
8 Thin Film Freezing – Superior Pulmonary Drug Delivery The Problem Our Solution Oral Inhaled Typically, 10% of oral drugs reach their target and often contain bulking agents, fillers, and high dosages contributing to unwanted side effects. Our TFF platform has shown the ability to deliver precise d
Slide 9: TFF Brittle Matrix Process and Powders
9 TFF Brittle Matrix Process and Powders Bulk Drug Material Brittle Matrix Powders
Slide 10: TFF Platform Advantages
10 TFF Platform Advantages Spray Drying Spray Freeze Drying Nano - Milling TFF Thermal Degradation ✘ x ✘ x Shear Stress ✘ ✘ ✘ x Air/Water Denaturation ✘ ✘ x x Technology Differentiators • Microparticles • Lower yield • Harder processing conditions • Microparticles • Lower yield • Variable particle s
Slide 11: A Revolutionary Technology Platform – Validated, Scalable, and IP-Protected
11 A Revolutionary Technology Platform – Validated, Scalable, and IP - Protected Clinical validation of TFF Pharma’s internal drug programs • Voriconazole Inhalation Powder (VORI) – Phase 1 trial completed – Final data from reactive airway study in 4Q’21 (completed) – Pursuing ODD*; Phase 2 trial in
Slide 12: GMP Manufacturing Readiness
12 GMP Manufacturing Readiness • TFF partnered with CoreRx and IriSys to manufacture non - clinical and clinical trial supplies for VORI and TAC. CoreRx has capacity to support long - term commercial supplies. Third CRO, Experic, to install Thin Film Freezing GMP processing line and specialized asso
Slide 13: Two-pronged Strategy For Leveraging TFF Formulations
13 Two - pronged Strategy For Leveraging TFF Formulations and Maximizing Value In - house Development Identify opportunities that address significant unmet medical need, and/or lower risk clinical pathway via 505(b)(2): – TFF Voriconazole (VORI) for IPA/ABPA – TFF Tacrolimus (TAC) for lung transplan
Slide 14: Voriconazole Inhalation Powder (TFF VORI)
14 Voriconazole Inhalation Powder (TFF VORI) • IV/Oral voriconazole indication and side effects • TFF VORI preclinical and clinical data highlights • Clinical development plan and near - term data readouts • Market opportunity Target Indications: Invasive Pulmonary Aspergillosis (IPA) Allergic Bronc
Slide 15: TFF VORI targeted indication and clinical strategy
15 Targeted indication: Acute and chronic treatment of adults and pediatric patients 2 years - of - age and older with invasive pulmonary aspergillosis (IPA) and allergic bronchopulmonary aspergillosis (ABPA) and prophylaxis of IPA Preclinical POC data: • 3X better survival vs. amphotericin in IPA P
Slide 16: TFF VORI Preclinical and Clinical Data To Date
16 IV/Oral voriconazole (insert data chart and note if data have been presented/published) TFF VORI Preclinical and Clinical Data To Date • 13 - week tox supportive of clinical approach • 26 - week tox study under way to support registration • SAD/MAD Completed with doses up to 80 mg BID for 7 days
Slide 17: 2021 inflection points and market opportunity
17 2021 inflection points and catalytic events • 13 - week toxicology study complete (2Q’21) • Final data from reactive airway study (4Q’21) • Initiated Phase 2 study (1Q’22) Market opportunity and payor access* • Antifungal sales topped $4B 1 . However, an inhaled voriconazole for IPA and ABPA and
Slide 18: Tacrolimus Inhalation Powder (TFF TAC)
18 Tacrolimus Inhalation Powder (TFF TAC) • IV/oral tacrolimus indication and side effects • TFF TAC preclinical and clinical data highlights • Clinical development plan and near - term data readouts • Substantial market opportunity Target Indication: Prophylaxis of organ rejection in patients recei
Slide 19: TFF TAC Program (Inhaled Tacrolimus)
19 Targeted Indication: Prophylaxis of organ rejection in patients receiving lung transplants Preclinical POC Data: Rat lung transplant, asthma, peer - reviewed Clinical Safety Data: • Successfully completed single and multiple ascending dosing of four cohorts of healthy subjects in Phase 1 trial •
Slide 20: TFF TAC Preclinical and Clinical Data To-Date
20 IV/Oral voriconazole TFF TAC Preclinical and Clinical Data To - Date • 26 - week tox complete • NOAEL established • 3 - 4 - fold higher lung exposure than blood • SAD doses of 0.5, 1.0, 2.5, and 5.0 mg • No food effect observed (2.5 mg cohort) • MAD doses of 0.5 and 1.0 mg BID and 1.5 mg QD • MAD
Slide 21: TFF TAC Outlook
21 TFF TAC Outlook * Trinity Partners (third party market research firm); “TFF Forecast Update: TFF Tac - Lac and TFF VORI ; Final Report – Updated”; May 5th, 2021 ** Granted Orphan Drug Designation 2021 inflection points and catalytic events • Six - month toxicology study completed (1Q’21) • Phase
Slide 22: 2021 Clinical Catalysts
22 x Q1 TAC: 6 - month tox completed, Phase 1 SAD dosing complete NICLO: Pre - IND submission, oral tox study start x Q2 VORI: 13 - week tox complete; release of Phase I data NICLO: Inhaled tox study start, oral tox complete x Q3 VORI: 26 - week tox study initiated TAC: Phase 1b topline data AUGMENT
Slide 23: 2022 Expected Clinical Catalysts
23 Q1 VORI: Phase 2 – initiation TAC: Phase 2 – initiation Niclo: Phase 1 – Completion of Phase 1 Aug: CMC – engineering run complete, Initiation of tox study Q2 VORI: Phase 2 – study ongoing TAC: Phase 2 – study ongoing Niclo: IND filing for Phase 2 start* Aug: GMP mAb Drug Substance Manufacturing
Slide 24: Business Development - The Power of the TFF Platform
24 Business Development - The Power of the TFF Platform Under Consideration for Potential Development by TFF Government/ Academic Partnerships CRADA agreement with USAMRIID t o formulate dry powder neutralizing antibodies against national priority biodefense threats LEIDOS/DARPA contract R&D collabo
Slide 25: Disclosed Collaboration Partners
25 Disclosed Collaboration Partners
Slide 26: Vaccine Programs
26 Vaccine Programs R&D to evaluate Thin Film Freezing technology to formulate dry powder universal influenza vaccines for pulmonary delivery with one of the world’s leading research institutions in vaccine development • Collaboration between TFF, UT Austin and University of Georgia’s world renowned
Slide 27: Monoclonal Antibodies and Antivirals for COVID
27 Monoclonal Antibodies and Antivirals for COVID - 19 Worldwide Joint Development Agreement for COVID - 19 monoclonal antibody therapies with Augmenta Bioworks. Collaboration on first - of - its - kind uses of Thin Film Freezing technology applied to monoclonal antibodies (mAbs) • Joint Development
Slide 28: Next-Gen Chemical and Biological Protection
28 Next - Gen Chemical and Biological Protection 28 Thin Film Freezing platform to be used to rapidly neutralize chemical and biological threats at vulnerable tissue barriers to increase soldier protection and decrease operational burden under DARPA’s Personalized Protective Biosystems (PPB) Program
Slide 29: Bacteriophage-based Biotherapeutic and Cannabis Opportunity
29 Bacteriophage - based Biotherapeutic 29 Letter of Intent for a Collaboration, Development and License Agreement. Felix Biotechnology would obtain worldwide license for T FF technology to develop a novel, bacteriophage - based biotherapeutic • In exchange for TFF technology license, Felix would ag
Slide 30: Collaborations
30 Collaborations Collaboration with Pfizer to evaluate the Thin Film Freezing technology with multiple proprietary drug candidates of Pfizer • TFF to formulate and perform feasibility testing on multiple Pfizer drug candidates utilizing TFF’s proprietary thin film freezing technology • Pfizer’s pro
Slide 31: TFF Pharma – Catalent Collaboration Agreement
31 TFF Pharma – Catalent Collaboration Agreement 31 Catalent will introduce their customer base to TFF’s proprietary and innovative Thin Film Freezing technology Catalent to provide CDMO services to any referred client that licenses and partners TFF technology Collaboration focused on development of
Slide 32: Key Takeaways
32 Key Takeaways Revolutionary platform enabling inhalable drug delivery across the entire spectrum of pharmaceutical agents (small & large molecules, biologics, vaccines, mRNA), targeting multiple $Billion - plus markets Two proprietary, high commercial and lower risk clinical programs (TFF VORI &
Slide 33: PHARMACEUTICALS
PHARMACEUTICALS
Slide 34: Endnotes
34 ENDNOTES 1. Antifungal Market Growth - 2013. Global Data Research Report https://www.globaldata.com/ (last accessed February 15, 2019). TFF Pharmaceuticals Estimates Q1 2019 2. Growth of Global Immunosuppressant Market for Acute Rejection - 2013. Global Data Research Report https://www.globaldata
TFF Pharmaceuticals — Investor Presentation (March 2022) on 6ix